The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. ##STR00001## wherein X.sup.1 is CH or N, X.sup.2 is CR.sup.5 or N, Y is O or S, R.sup.1 is inter alia C.sub.2-C.sub.8-alkyl, C.sub.2-C.sub.8-alkenyl, C.sub.1-C.sub.4-fluoroalkyl, C.sub.3-C.sub.8-cycloalkyl, C.sub.5-C.sub.8-cycloalkyl carrying a fused benzene ring, or a moiety Z.sup.1Ar.sup.1; R.sup.2 is a radical of the formula CR.sup.21R.sup.22R.sup.23 or phenyl or 5- or 6-membered hetaryl having 1, 2 or 3 heteroatoms as ring members which are selected from O, S and N, where phenyl and monocyclic hetaryl are unsubstituted or may carry 1, 2 or 3 identical or different substituents R.sup.a, R.sup.3 is inter alia hydrogen, C.sub.1-C.sub.8-alkyl, C.sub.2-C.sub.8-alkenyl, C.sub.1-C.sub.4-fluoroalkyl, C.sub.3-C.sub.8-cycloalkyl, etc, or R.sup.2 and R.sup.3 together with the nitrogen atom, to which they are bound form an optionally substituted saturated 5- to 7-membered heterocyclic ring which, in addition to the nitrogen atom, may have 1 or 2 further heteroatoms or heteroatom containing groups selected from the group of O, N, S, SO and SO.sub.2; R.sup.4 is inter alia C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.4-fluoroalkyl, C.sub.3-C.sub.6-cycloalkyl, C.sub.3-C.sub.6-cycloalkyl-C.sub.1-C.sub.4-alkyl or Z.sup.4Ar.sup.4; R.sup.5 is inter alia hydrogen, halogen, C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.4-fluoroalkyl, C.sub.1-C.sub.4-alkoxy, C.sub.1-C.sub.4-fluoroalkoxy, Z.sup.5Ar.sup.5, OZ.sup.5Ar.sup.5, etc; where Z.sup.1 to Z.sup.5, Ar.sup.1 to Ar.sup.5, R.sup.a, R.sup.21, R.sup.22 and R.sup.23 are as defined in the claims.

Provided is a liquid crystal compound that has high stability to heat, light and so forth, a high clearing point, low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large negative dielectric anisotropy, a suitable elastic constant and excellent compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound and a liquid crystal display device including the composition. The compound is represented by formula (1). ##STR00001## For example, R.sup.1 is alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons or alkenyl having 2 to 10 carbons; R.sup.2 is alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons or alkenyl having 3 to 10 carbons; ring A.sup.1 is 1,4-cyclohexylene or 1,4-phenylene; ring A.sup.2 is 1,4-cyclohexylene or 1,4-phenylene; Z.sup.1 and Z.sup.2 are a single bond; Z.sup.3 is O or a single bond; and L.sup.1 is F, CF.sub.3 or CF.sub.2H.

Provided is a liquid crystal compound that has high stability to heat, light and so forth, a high clearing point, low minimum temperature of a liquid crystal phase, small viscosity, suitable optical anisotropy, large negative dielectric anisotropy, a suitable elastic constant and excellent compatibility with other liquid crystal compounds, a liquid crystal composition containing the compound and a liquid crystal display device including the composition. The compound is represented by formula (1). ##STR00001## For example, R.sup.1 is alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons or alkenyl having 2 to 10 carbons; R.sup.2 is alkyl having 1 to 10 carbons, alkoxy having 1 to 9 carbons or alkenyl having 3 to 10 carbons; ring A.sup.1 is 1,4-cyclohexylene or 1,4-phenylene; ring A.sup.2 is 1,4-cyclohexylene or 1,4-phenylene; Z.sup.1 and Z.sup.2 are a single bond; Z.sup.3 is O or a single bond; and L.sup.1 is F, CF.sub.3 or CF.sub.2H.

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.

Disclosed are an organic electroluminescent device (organic EL device) having improved luminous efficiency, sufficiently secured driving stability, and a simple construction, and a material for an organic EL device. The material for an organic EL device includes a carborane compound having a structure in which at least one carborane ring and at least one dibenzothiophene ring are present, and the at least one carborane ring is bonded to the at least one dibenzothiophene ring at position 1, 2, or 3. In addition, the organic EL device includes, between an anode and a cathode laminated on a substrate, at least one organic layer, in which the at least one organic layer includes the carborane compound.

Disclosed are an organic electroluminescent device (organic EL device) having improved luminous efficiency, sufficiently secured driving stability, and a simple construction, and a material for an organic EL device. The material for an organic EL device includes a carborane compound having a structure in which at least one carborane ring and at least one dibenzothiophene ring are present, and the at least one carborane ring is bonded to the at least one dibenzothiophene ring at position 1, 2, or 3. In addition, the organic EL device includes, between an anode and a cathode laminated on a substrate, at least one organic layer, in which the at least one organic layer includes the carborane compound.

This invention relates to compounds that are agonists of the muscarinic M.sub.1 receptor or M.sub.1 and M.sub.4 receptors and which are useful in the treatment of muscarinic M.sub.1 or M.sub.1/M.sub.4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula ##STR00001##
wherein Q.sup.4, Q.sup.5, R.sup.5, p, V, Q.sup.1, Q.sup.2, X.sup.1, X.sup.2 and W are defined herein.

This invention relates to compounds that are agonists of the muscarinic M.sub.1 receptor or M.sub.1 and M.sub.4 receptors and which are useful in the treatment of muscarinic M.sub.1 or M.sub.1/M.sub.4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula ##STR00001##
wherein Q.sup.4, Q.sup.5, R.sup.5, p, V, Q.sup.1, Q.sup.2, X.sup.1, X.sup.2 and W are defined herein.

This disclosure provides a family of compounds that absorb and fluoresce in the short wave infrared region (SWIR, optionally 1000 nm to 1300 nm), including hydrophilic compounds that exhibit absorption and emission spectral profiles in aqueous solutions substantially similar to those observed in organic solvents such as methanol or DMSO. The compounds can be chemically linked to biomolecules including proteins, nucleic acids, and therapeutic small molecules. The compounds are useful for imaging in a variety of medical, biological and diagnostic applications, including SWIR in vivo imaging of regions of interest within a mammal.